JP6894837B2 - ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法 - Google Patents

ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法 Download PDF

Info

Publication number
JP6894837B2
JP6894837B2 JP2017516840A JP2017516840A JP6894837B2 JP 6894837 B2 JP6894837 B2 JP 6894837B2 JP 2017516840 A JP2017516840 A JP 2017516840A JP 2017516840 A JP2017516840 A JP 2017516840A JP 6894837 B2 JP6894837 B2 JP 6894837B2
Authority
JP
Japan
Prior art keywords
kit
organ
injury
heme
protoporphyrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017516840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535522A (ja
Inventor
ゼーガー，リチャード
ジョンソン，アリ・シー・エム
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター, フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2017535522A publication Critical patent/JP2017535522A/ja
Priority to JP2021093465A priority Critical patent/JP2021130710A/ja
Application granted granted Critical
Publication of JP6894837B2 publication Critical patent/JP6894837B2/ja
Priority to JP2022202892A priority patent/JP2023054797A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dentistry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2017516840A 2014-09-29 2015-09-28 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法 Active JP6894837B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021093465A JP2021130710A (ja) 2014-09-29 2021-06-03 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
JP2022202892A JP2023054797A (ja) 2014-09-29 2022-12-20 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462057047P 2014-09-29 2014-09-29
US62/057,047 2014-09-29
US201562212232P 2015-08-31 2015-08-31
US62/212,232 2015-08-31
PCT/US2015/052676 WO2016053882A2 (en) 2014-09-29 2015-09-28 Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021093465A Division JP2021130710A (ja) 2014-09-29 2021-06-03 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法

Publications (2)

Publication Number Publication Date
JP2017535522A JP2017535522A (ja) 2017-11-30
JP6894837B2 true JP6894837B2 (ja) 2021-06-30

Family

ID=55631749

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017516840A Active JP6894837B2 (ja) 2014-09-29 2015-09-28 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
JP2021093465A Pending JP2021130710A (ja) 2014-09-29 2021-06-03 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
JP2022202892A Pending JP2023054797A (ja) 2014-09-29 2022-12-20 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021093465A Pending JP2021130710A (ja) 2014-09-29 2021-06-03 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
JP2022202892A Pending JP2023054797A (ja) 2014-09-29 2022-12-20 ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法

Country Status (22)

Country Link
US (5) US10639321B2 (lt)
EP (2) EP4327808A3 (lt)
JP (3) JP6894837B2 (lt)
KR (2) KR102578217B1 (lt)
CN (2) CN107072190B (lt)
AU (2) AU2015324103C1 (lt)
BR (1) BR112017006531B1 (lt)
CA (2) CA3220985A1 (lt)
DK (1) DK3200582T3 (lt)
FI (1) FI3200582T3 (lt)
HR (1) HRP20240229T1 (lt)
IL (3) IL287607B (lt)
LT (1) LT3200582T (lt)
MX (1) MX2017004148A (lt)
NZ (1) NZ729754A (lt)
PL (1) PL3200582T3 (lt)
PT (1) PT3200582T (lt)
RS (1) RS65182B1 (lt)
SG (2) SG10201902831UA (lt)
SI (1) SI3200582T1 (lt)
WO (1) WO2016053882A2 (lt)
ZA (1) ZA202305280B (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3200582T3 (pl) 2014-09-29 2024-04-08 Fred Hutchinson Cancer Center Kompozycje, zestawy i sposoby indukcji nabytej cytororoporności z wykorzystaniem induktorów białek stresowych
US20190358242A1 (en) * 2017-02-08 2019-11-28 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
CA3238712A1 (en) * 2018-03-27 2019-10-03 Exact Sciences Corporation Method for stabilizing hemoglobin and reagents for performing the same
BR112020023943A2 (pt) * 2018-05-24 2021-02-09 Renibus Therapeutics, Inc. métodos de tratamento de pacientes em risco de lesão renal e insuficiência renal
LT3930686T (lt) 2019-02-28 2023-10-10 Renibus Therapeutics, Inc. Naujos geležies kompozicijos ir jų gamybos bei naudojimo būdai
WO2022019235A1 (ja) * 2020-07-22 2022-01-27 国立大学法人 新潟大学 腎障害の抑制におけるビタミンｂ１２の利用
JP2023541606A (ja) * 2020-09-11 2023-10-03 レニバス・セラピューティクス・インコーポレイテッド 腎臓を保護しながらがんを治療するための方法
US20230390229A1 (en) * 2021-03-12 2023-12-07 Niigata University Prevention of kidney injury induced by hemolytic reaction
US20230404958A1 (en) * 2021-03-12 2023-12-21 Niigata University Agent for inhibiting renal damage induced by rhabdomyolysis
US20230023467A1 (en) * 2021-07-12 2023-01-26 Renibus Therapeutics, Inc. Metal protoporphyrin for treatment of bk virus
CN114891707B (zh) * 2022-05-20 2024-04-05 中国科学院微生物研究所 重组菌株及其全细胞催化生产胆红素的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579533A (en) 1968-03-18 1971-05-18 Antioch College Preparation of porphin,substituted porphin and metal chelates thereof
GB1596298A (en) 1977-04-07 1981-08-26 Morgan Ltd P K Method of and apparatus for detecting or measuring changes in the cross-sectional area of a non-magnetic object
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4692440A (en) 1985-03-25 1987-09-08 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4668670A (en) 1986-06-20 1987-05-26 The Rockefeller University Tin diiododeuteroporphyrin and therapeutic use thereof
US4782049A (en) 1986-12-08 1988-11-01 The Rockefeller University Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US5108767A (en) 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
US5274090A (en) 1992-11-09 1993-12-28 The Board Of Trustees Of The Leland Stanford Junior University Tetraphenylporphyrin compounds and method
WO1994028906A1 (en) 1993-06-14 1994-12-22 The Rockefeller University Treatment of neonatal hyperbilirubin with metalloporphyrin
US5804551A (en) * 1996-11-12 1998-09-08 Baxter International Inc. Pretraumatic use of hemoglobin
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1231942A1 (en) 1999-10-15 2002-08-21 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
US6573258B2 (en) 2000-09-27 2003-06-03 Frontier Scientific, Inc. Photodynamic porphyrin antimicrobial agents
US6517492B2 (en) 2001-02-22 2003-02-11 Texon Technologies Ltd. Method and apparatus for assessment of cardiac function by monitoring movement of the trachea
AR037699A1 (es) 2001-12-04 2004-12-01 Monsanto Technology Llc Maiz transgenico con fenotipo mejorado
US7375216B2 (en) 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
US6818763B2 (en) 2002-06-04 2004-11-16 Wellspring Pharmaceutical Corporation Preparation of metal mesoporphyrin halide compounds
PT1546336E (pt) 2002-09-18 2012-04-09 Mendel Biotechnology Inc Polinucleótidos e polipéptidos em plantas
AU2003286474A1 (en) * 2002-10-18 2004-05-04 The General Hospital Corporation Compositions, solutions, and methods used for transplantation
JP2004307404A (ja) * 2003-04-08 2004-11-04 Nipro Corp 人工酸素運搬体を含む医薬組成物
US7008937B2 (en) 2003-06-10 2006-03-07 Frontier Scientific, Inc. Porphyrins and metalloporphyrins for inhibiting heme iron uptake
US7067659B2 (en) 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
WO2005107793A2 (en) 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
CA2573927A1 (en) 2004-07-15 2006-01-19 The University Of Sydney Porphyrin linked metronidazole against gum disease: porphyromonas gingivalis
US7585527B2 (en) 2005-09-19 2009-09-08 Bala Venkataraman Composition and method for treating iron deficiency anemia
CN104116745B (zh) 2006-10-04 2018-07-06 婴儿护理药品公司 包含锡泊芬的组合物
WO2008156868A2 (en) 2007-06-20 2008-12-24 Baum Seth J Compositions and methods of treating chronic kidney disease
WO2009029836A2 (en) * 2007-08-31 2009-03-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes
DK2691398T3 (en) 2011-03-30 2017-01-16 Infacare Pharmaceutical Corp Methods for synthesizing metal mesoporphyrins
CN103355655A (zh) * 2012-03-30 2013-10-23 北京因科瑞斯医药科技有限公司 一种具有改善营养性贫血功能的组合物及其制备方法
US9350026B2 (en) 2012-09-28 2016-05-24 Uchicago Argonne, Llc Nanofibrous electrocatalysts
US20140273273A1 (en) * 2012-11-01 2014-09-18 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk
MX2016010328A (es) 2014-02-10 2017-02-06 Hutchinson Fred Cancer Res Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CN107074868B (zh) 2014-05-05 2019-05-14 国家科学研究中心 用于将co2选择性电化学还原为co的卟啉分子催化剂
PL3200582T3 (pl) 2014-09-29 2024-04-08 Fred Hutchinson Cancer Center Kompozycje, zestawy i sposoby indukcji nabytej cytororoporności z wykorzystaniem induktorów białek stresowych

Also Published As

Publication number Publication date
JP2021130710A (ja) 2021-09-09
WO2016053882A3 (en) 2016-05-06
WO2016053882A2 (en) 2016-04-07
SG11201702080UA (en) 2017-04-27
IL287607A (en) 2021-12-01
US20160271164A1 (en) 2016-09-22
FI3200582T3 (fi) 2024-02-14
EP3200582B1 (en) 2023-11-15
CN112057470A (zh) 2020-12-11
AU2015324103B2 (en) 2020-05-21
KR20170057433A (ko) 2017-05-24
EP3200582A4 (en) 2018-04-04
HRP20240229T1 (hr) 2024-04-26
IL274891A (en) 2020-07-30
IL274891B (en) 2021-12-01
MX2017004148A (es) 2017-07-07
IL251455B (en) 2020-06-30
KR102578217B1 (ko) 2023-09-15
IL251455A0 (en) 2017-05-29
US20170112869A1 (en) 2017-04-27
LT3200582T (lt) 2024-03-12
NZ729754A (en) 2023-01-27
US11878029B2 (en) 2024-01-23
CN107072190B (zh) 2020-10-09
EP4327808A2 (en) 2024-02-28
JP2023054797A (ja) 2023-04-14
JP2017535522A (ja) 2017-11-30
EP3200582A2 (en) 2017-08-09
PL3200582T3 (pl) 2024-04-08
SI3200582T1 (sl) 2024-04-30
US10912793B2 (en) 2021-02-09
DK3200582T3 (da) 2024-02-19
CN107072190A (zh) 2017-08-18
PT3200582T (pt) 2024-02-19
US20190091255A1 (en) 2019-03-28
BR112017006531B1 (pt) 2023-01-24
US10639321B2 (en) 2020-05-05
RS65182B1 (sr) 2024-03-29
US20240108646A1 (en) 2024-04-04
BR112017006531A2 (pt) 2017-12-19
AU2015324103A1 (en) 2017-03-23
US20210275567A1 (en) 2021-09-09
AU2015324103C1 (en) 2020-08-20
ZA202305280B (en) 2023-12-20
EP4327808A3 (en) 2024-05-15
CA2963089A1 (en) 2016-04-07
CA3220985A1 (en) 2016-04-07
IL287607B (en) 2022-07-01
SG10201902831UA (en) 2019-04-29
US9844563B2 (en) 2017-12-19
KR20230132636A (ko) 2023-09-15
AU2020202652A1 (en) 2020-05-14
CN112057470B (zh) 2022-11-15
AU2020202652B2 (en) 2022-06-30
CA2963089C (en) 2024-01-09

Similar Documents

Publication Publication Date Title
JP6894837B2 (ja) ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
US20230416328A1 (en) C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
WO2010045310A1 (en) Method of treating thrombocytopenia
US20190358242A1 (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
US20190106454A1 (en) Compounds linked with a saccharide metal complex and uses thereof
JP2023522984A (ja) 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
Arshad et al. Modulation of Oxidative Status under Naphthalene Induced Nephrotoxicity in Mice
JP2012102029A (ja) アセトアミノフェン肝傷害治療剤
JP2022502048A (ja) 脂肪肝疾患を治療するためのグルタミン合成酵素の使用
JP2021518417A (ja) 肺の修復に関する方法および組成物
AU2007201085A1 (en) Copper lowering treatment of inflammatory and fibrotic diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210604

R150 Certificate of patent or registration of utility model

Ref document number: 6894837

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150